Sanara MedTech (SMTI) Stock Price, News & Analysis

Company Overview

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies. The company offers a range of balloon-based dilation products, including multi­sinus dilation systems, as well as adjunctive instruments for tissue access and endoscopic visualization. Its ENT platform is complemented by specialized energy‐based ablation technologies and implantable devices designed to address complex nasal and ear disorders.

Following its establishment through a business combination in early 2022, Sanara MedTech continues to invest in clinical studies and product enhancements aimed at broadening indications and improving procedural efficiency. The company collaborates with leading physicians and academic centers to validate its technologies and expand training programs that support adoption by surgeons worldwide.

Headquartered in Irvine, California, Sanara MedTech serves markets across North America, Europe, Latin America and Asia Pacific through a combination of direct sales teams and distributor partnerships. Its leadership team comprises experienced executives and clinicians with backgrounds in medical device innovation, regulatory affairs and global commercialization. Looking forward, the company is positioned to leverage its established technology platforms to pursue growth opportunities in ENT and adjacent specialties.

Key Stats

• Today's Range: $31.48 to $35.00
• 50-Day Range: $24.16 to $35.75
• 52-Week Range: $23.53 to $39.08
• Volume: 41,226 shs
• Average Volume: 21,160 shs
• Market Capitalization: $289.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Hold

Sanara MedTech Stock Analysis - MarketRank™

Sanara MedTech scored higher than 38% of companies evaluated by MarketBeat, and ranked 571st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Sanara MedTech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Sanara MedTech has a consensus price target of $50.00, representing about 53.9% upside from its current price of $32.50.

Amount of Analyst Coverage

Sanara MedTech has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sanara MedTech are expected to grow in the coming year, from ($1.10) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanara MedTech is -27.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanara MedTech is -27.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sanara MedTech has a P/B Ratio of 7.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.47% of the float of Sanara MedTech has been sold short.

Short Interest Ratio / Days to Cover

Sanara MedTech has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Sanara MedTech has recently decreased by 5.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sanara MedTech does not currently pay a dividend.

Dividend Growth

Sanara MedTech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.47% of the float of Sanara MedTech has been sold short.

Short Interest Ratio / Days to Cover

Sanara MedTech has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Sanara MedTech has recently decreased by 5.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Sanara MedTech this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanara MedTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.60% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.10% of the stock of Sanara MedTech is held by institutions.

SMTI Stock Analysis - Frequently Asked Questions

How have SMTI shares performed this year?

Sanara MedTech's stock was trading at $33.20 at the beginning of the year. Since then, SMTI stock has decreased by 2.1% and is now trading at $32.4950.

How were Sanara MedTech's earnings last quarter?

Sanara MedTech Inc. (NASDAQ:SMTI) released its earnings results on Wednesday, August, 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.10. The business had revenue of $25.83 million for the quarter, compared to analysts' expectations of $25.15 million. Sanara MedTech had a negative net margin of 10.22% and a negative trailing twelve-month return on equity of 26.43%.
Read the conference call transcript.

Who are Sanara MedTech's major shareholders?

Top institutional shareholders of Sanara MedTech include Salem Investment Counselors Inc. (0.10%).
View institutional ownership trends.

How do I buy shares of Sanara MedTech?

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sanara MedTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SMTI
• CIK: 714256
• Web: www.wndm.com
• Phone: (817) 529-2300
• Fax: N/A
• Employees: 60
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Sanara MedTech: $50.00
• High Price Target: $54.00
• Low Price Target: $46.00
• Potential Upside/Downside: +54.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.66 million
• Net Margins: -10.22%
• Pretax Margin: -10.42%
• Return on Equity: -26.43%
• Return on Assets: -10.69%

Debt

• Debt-to-Equity Ratio: 1.25
• Current Ratio: 2.26
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $86.67 million
• Price / Sales: 3.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.45 per share
• Price / Book: 7.27

Miscellaneous

• Outstanding Shares: 8,900,000
• Free Float: 5,110,000
• Market Cap: $287.74 million
• Optionable: Not Optionable
• Beta: 1.21